WP3: New methods for prospective design and analysis of series of studies
In WP3, appropriate statistical methods and guidance to prospectively plan and analyse series of trials will be delivered. Hence, WP3 builds upon the foundations laid by WP2 for individual trial designs, and adds the incorporation of historical information, among others, from patient registries and patients’ views on relevant trial outcomes from WP4.
Researchers in WP3 will include the following innovations:
- New methodology for prospective planning of a sequential meta-analysis;
- New methodology to integrate evidence across all phases of drug development;
- New methodology to allow a more effective use of patient registry data;
- Adapted standards of evidence for series of clinical trials.
Leader WP3: Prof. dr. Kit C.B. Roes, University Medical Center Utrecht